Nikhil Kapila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nikhil Kapila has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Gianina Flocco
Digestive Diseases Institute, Cleveland Clinic, Cleveland, OH, USA
4 shared publicationsFayssa Salomon
Department of Internal Medicine, Cleveland Clinic Florida, Weston, FL, USA
2 shared publicationsFernando J. Castro
Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL, USA
2 shared publicationsHarjinder Singh
Department of Gastroenterology, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL, USA
2 shared publicationsJason M. Vanatta
Department of Transplant, Cleveland Clinic Florida, Weston, Florida
2 shared publicationsKawtar Al Khalloufi
Department of Transplant, Cleveland Clinic Florida, Weston, FL, USA
2 shared publications
Latest Publications
- 16 May 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 22 (1) , 1-6
Endocrinology for the hepatologist
- 16 May 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 22 (1) , 1-6
Endocrinology for the hepatologist
- Open Access
- 16 January 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 11 (2) , 316-321
Liver transplantation amidst the COVID-19 era: Our center’s experience
Coronavirus disease 2019 significantly impacted the liver transplant process worldwide. Consequently, it brought significant challenges and limitations to transplant policies and organ allocation forcing liver transplant centers to adjust their protocols to ensure maximum benefit and avoid harm to their patients. Our center, like many others, was obliged to adapt to the challenges. This paper provided an overview of the effects of coronavirus disease 2019 on liver transplantations and detailed our center’s experience and efforts during this unprecedented pandemic to serve as a guide for future public health crises.
- 16 January 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 11 (2) , 316-321
Open AccessLiver transplantation amidst the COVID-19 era: Our center’s experience
Coronavirus disease 2019 significantly impacted the liver transplant process worldwide. Consequently, it brought significant challenges and limitations to transplant policies and organ allocation forcing liver transplant centers to adjust their protocols to ensure maximum benefit and avoid harm to their patients. Our center, like many others, was obliged to adapt to the challenges. This paper provided an overview of the effects of coronavirus disease 2019 on liver transplantations and detailed our center’s experience and efforts during this unprecedented pandemic to serve as a guide for future public health crises.
- 25 January 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (1) , 365-368
An Evaluation of the Fecal Microbiome in Lynch Syndrome
Purpose There is limited data regarding the fecal microbiome findings in patients with Lynch syndrome. We aimed to study the fecal micobiome of patients with Lynch syndrome with and without cancer. Methods We performed an observational study comparing the fecal microbiome of patients with Lynch syndrome (LS) with cancer with those without cancer. We included subjects older than 18 years with LS and excluded those with a history of colectomy or inflammatory bowel disease. We analyzed their fecal microbiome by 16S ribosomal subunit PCR amplification and performed comparative analyses. Results Eight patients were included: 3 of these with LS and cancer (LS-C) and 5 patients with LS and no cancer (LS-NC). We found non-significant differences at the phyla and genera level between the LS-C and LS-NC groups. At the phyla level, LS-C patients had a higher percentage of Bacteroidetes (42.2% vs. 28.5%; P = 0.068) and Verrucomicrobia (0.644% vs 0.0007%; P = 0.10), and a lower percentage of Firmicutes (48.3% vs. 65.4%; P = 0.078). At the genus level, LS-C patients had a higher rate of Akkermania (0.766% vs. 0.001%; P = 0.11). LS-C patients with endometrial cancer had a higher rate of Bacteroides (37.4% vs 17.3%; P = 0.10). LS-C patients had a lower rate of Pseudobutyrvibrio (0.74% vs. 2.71%; P = 0.10). Conclusions The fecal microbiome of LS patients with extraintestinal cancer differs that of LS patients without cancer. Further studies are needed to explore microbiome changes in these high risk patients.
- 25 January 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (1) , 365-368
An Evaluation of the Fecal Microbiome in Lynch Syndrome
Purpose There is limited data regarding the fecal microbiome findings in patients with Lynch syndrome. We aimed to study the fecal micobiome of patients with Lynch syndrome with and without cancer. Methods We performed an observational study comparing the fecal microbiome of patients with Lynch syndrome (LS) with cancer with those without cancer. We included subjects older than 18 years with LS and excluded those with a history of colectomy or inflammatory bowel disease. We analyzed their fecal microbiome by 16S ribosomal subunit PCR amplification and performed comparative analyses. Results Eight patients were included: 3 of these with LS and cancer (LS-C) and 5 patients with LS and no cancer (LS-NC). We found non-significant differences at the phyla and genera level between the LS-C and LS-NC groups. At the phyla level, LS-C patients had a higher percentage of Bacteroidetes (42.2% vs. 28.5%; P = 0.068) and Verrucomicrobia (0.644% vs 0.0007%; P = 0.10), and a lower percentage of Firmicutes (48.3% vs. 65.4%; P = 0.078). At the genus level, LS-C patients had a higher rate of Akkermania (0.766% vs. 0.001%; P = 0.11). LS-C patients with endometrial cancer had a higher rate of Bacteroides (37.4% vs 17.3%; P = 0.10). LS-C patients had a lower rate of Pseudobutyrvibrio (0.74% vs. 2.71%; P = 0.10). Conclusions The fecal microbiome of LS patients with extraintestinal cancer differs that of LS patients without cancer. Further studies are needed to explore microbiome changes in these high risk patients.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 14
Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study
There is limited data on the use of anti-TNF agents in patients with concomitant cirrhosis. The aim of this study is to assess the safety of anti-TNF agents in patients with compensated cirrhosis who used these medications for the treatment of an underlying rheumatologic condition or IBD. Multicenter, retrospective, matched, case-control study. A one to three case-control match was performed. Adults who received anti-TNF therapy were matched to three adults with cirrhosis who did not receive anti-TNF therapy. Patients were matched for etiology of cirrhosis, MELD-Na and age. Primary outcome was the development of hepatic decompensation. Secondary outcomes included development of infectious complications, hepatocellular carcinoma (HCC), extra-hepatic malignancy, and mortality. Eighty patients with cirrhosis who received anti-TNF agents were matched with 240 controls. Median age was 57.2 years. Median MELD-Na for the anti-TNF cohort was seven and median MELD-Na for the controls was eight. The most common etiology of cirrhosis was NAFLD. Anti-TNF therapy did not increase risk of decompensation (HR: 0.91, 95% CI: 0.64–1.30, p = 0.61) nor influence the time to development of a decompensating event. Anti-TNF therapy did not increase the risk of hepatic mortality or need for liver transplantation (HR: 1.18, 95% CI: 0.55–2.53, p = 0.67). Anti-TNF therapy was not associated with an increased risk of serious infection (HR: 1.21, 95% CI: 0.68–2.17, p = 0.52), HCC (OR: 0.45, 95% CI: 0.13–1.57, p = 0.21), or extra-hepatic malignancy (OR: 0.82, 95% CI: 0.29–2.30, p = 0.71). Anti-TNF agents in patients with compensated cirrhosis does not influence the risk of decompensation, serious infections, transplant free survival, or malignancy.
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 14
Open AccessSafety of anti-TNF agents in patients with compensated cirrhosis: a case-control study
There is limited data on the use of anti-TNF agents in patients with concomitant cirrhosis. The aim of this study is to assess the safety of anti-TNF agents in patients with compensated cirrhosis who used these medications for the treatment of an underlying rheumatologic condition or IBD. Multicenter, retrospective, matched, case-control study. A one to three case-control match was performed. Adults who received anti-TNF therapy were matched to three adults with cirrhosis who did not receive anti-TNF therapy. Patients were matched for etiology of cirrhosis, MELD-Na and age. Primary outcome was the development of hepatic decompensation. Secondary outcomes included development of infectious complications, hepatocellular carcinoma (HCC), extra-hepatic malignancy, and mortality. Eighty patients with cirrhosis who received anti-TNF agents were matched with 240 controls. Median age was 57.2 years. Median MELD-Na for the anti-TNF cohort was seven and median MELD-Na for the controls was eight. The most common etiology of cirrhosis was NAFLD. Anti-TNF therapy did not increase risk of decompensation (HR: 0.91, 95% CI: 0.64–1.30, p = 0.61) nor influence the time to development of a decompensating event. Anti-TNF therapy did not increase the risk of hepatic mortality or need for liver transplantation (HR: 1.18, 95% CI: 0.55–2.53, p = 0.67). Anti-TNF therapy was not associated with an increased risk of serious infection (HR: 1.21, 95% CI: 0.68–2.17, p = 0.52), HCC (OR: 0.45, 95% CI: 0.13–1.57, p = 0.21), or extra-hepatic malignancy (OR: 0.82, 95% CI: 0.29–2.30, p = 0.71). Anti-TNF agents in patients with compensated cirrhosis does not influence the risk of decompensation, serious infections, transplant free survival, or malignancy.
- Open Access
- 26 August 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (2) , 600-605
Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era
- 26 August 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (2) , 600-605
Open AccessFibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era
- Open Access
- 4 June 2019
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (X) , 1-5
Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
Background and Aims: Hepatitis C virus (HCV)-infected organs are underutilized. We aimed to assess the safety and efficacy of direct-acting antiviral agents (DAAs) therapy in HCV viremic patients who are transplanted with a liver from a HCV viremic donor.
- 4 June 2019
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (X) , 1-5
Open AccessTransplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
Background and Aims: Hepatitis C virus (HCV)-infected organs are underutilized. We aimed to assess the safety and efficacy of direct-acting antiviral agents (DAAs) therapy in HCV viremic patients who are transplanted with a liver from a HCV viremic donor.
- 1 May 2019
- Published by Elsevier in Gastroenterology
- Vol. 156 (6)
507 – Safety of Anti-Tumor Necrosis Agents in Patients with Cirrhosis
- 1 May 2019
- Published by Elsevier in Gastroenterology
- Vol. 156 (6)
507 – Safety of Anti-Tumor Necrosis Agents in Patients with Cirrhosis
- 6 April 2019
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (10) , 2798-2805
Open Access Colonoscopy for Colorectal Cancer Prevention: An Evaluation of Appropriateness and Quality
Open access colonoscopy (OAC) has gained widespread acceptance and has the potential to increase colorectal cancer (CRC) screening. However, there is little data evaluating its appropriateness for CRC prevention.
- 6 April 2019
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (10) , 2798-2805
Open Access Colonoscopy for Colorectal Cancer Prevention: An Evaluation of Appropriateness and Quality
Open access colonoscopy (OAC) has gained widespread acceptance and has the potential to increase colorectal cancer (CRC) screening. However, there is little data evaluating its appropriateness for CRC prevention.
- 18 November 2018
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 26 (3) , 407-409
Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin
- 18 November 2018
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 26 (3) , 407-409
Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin
- Open Access
- 31 July 2018
- Published by Springer Nature in Cureus
- Vol. 10 (7) , e3080
The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
Vedolizumab is a humanized monoclonal α4β7 integrin antibody used in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Limited data are available on the use of vedolizumab in patients with concurrent cirrhosis and inflammatory bowel disease (IBD). Patients with cirrhosis are unique, as they have a predilection for developing opportunistic infections and malignancies. Additionally, it is not known if vedolizumab alters the natural course of cirrhosis. We report our experience in three patients with concomitant CD and cirrhosis, who were treated with vedolizumab. In our limited cohort, all the three patients tolerated vedolizumab well. None of them experienced significant infectious complications, nor did any have decompensated cirrhosis. Our limited series suggest that vedolizumab is well tolerated in patients with compensated cirrhosis.
- 31 July 2018
- Published by Springer Nature in Cureus
- Vol. 10 (7) , e3080
Open AccessThe Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
Vedolizumab is a humanized monoclonal α4β7 integrin antibody used in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Limited data are available on the use of vedolizumab in patients with concurrent cirrhosis and inflammatory bowel disease (IBD). Patients with cirrhosis are unique, as they have a predilection for developing opportunistic infections and malignancies. Additionally, it is not known if vedolizumab alters the natural course of cirrhosis. We report our experience in three patients with concomitant CD and cirrhosis, who were treated with vedolizumab. In our limited cohort, all the three patients tolerated vedolizumab well. None of them experienced significant infectious complications, nor did any have decompensated cirrhosis. Our limited series suggest that vedolizumab is well tolerated in patients with compensated cirrhosis.